|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM164733779 |
| 003 |
DE-627 |
| 005 |
20231223103147.0 |
| 007 |
tu |
| 008 |
231223s2006 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0549.xml
|
| 035 |
|
|
|a (DE-627)NLM164733779
|
| 035 |
|
|
|a (NLM)16904380
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Daniels, Tracy R
|e verfasserin
|4 aut
|
| 245 |
1 |
4 |
|a The transferrin receptor part I
|b Biology and targeting with cytotoxic antibodies for the treatment of cancer
|
| 264 |
|
1 |
|c 2006
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 06.12.2006
|
| 500 |
|
|
|a Date Revised 08.04.2022
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a The transferrin receptor (TfR) is a cell membrane-associated glycoprotein involved in the cellular uptake of iron and in the regulation of cell growth. Iron uptake occurs via the internalization of iron-loaded transferrin (Tf) mediated by the interaction with the TfR. In addition, the TfR may also contain other growth regulatory properties in certain normal and malignant cells. The elevated levels of TfR in malignancies, its relevance in cancer, and the extracellular accessibility of this molecule make it an excellent antigen for the treatment of cancer using antibodies. The TfR can be targeted by monoclonal antibodies specific for the extracellular domain of the receptor. In this review, we summarize advancements in the basic physiology of the TfR including structure, function, and expression. We also discuss the efficacy of targeting the TfR using cytotoxic antibodies that inhibit cell growth and/or induce apoptosis in targeted malignant cells
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, N.I.H., Extramural
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
7 |
|a Antibodies, Monoclonal
|2 NLM
|
| 650 |
|
7 |
|a Receptors, Transferrin
|2 NLM
|
| 650 |
|
7 |
|a TFR2 protein, human
|2 NLM
|
| 650 |
|
7 |
|a Transferrin
|2 NLM
|
| 650 |
|
7 |
|a Iron
|2 NLM
|
| 650 |
|
7 |
|a E1UOL152H7
|2 NLM
|
| 700 |
1 |
|
|a Delgado, Tracie
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Rodriguez, Jose A
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Helguera, Gustavo
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Penichet, Manuel L
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 121(2006), 2 vom: 15. Nov., Seite 144-58
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:121
|g year:2006
|g number:2
|g day:15
|g month:11
|g pages:144-58
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 121
|j 2006
|e 2
|b 15
|c 11
|h 144-58
|